Initiation of First-in-Human Phase 1 Clinical Trial for Monotherapy Dose Escalation  Earns $2.5 Million Milestone for IND Acceptance from Partner LG Chem Life Sciences CAMBRIDGE, Mass. , May 16, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE), an innovative clinical stage immunotherapy

CAMBRIDGE, Mass. , June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that

CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc., an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, today announced that Kenneth Pienta, M.D., will serve as acting Chief Medical Officer

Novel positron emission tomography approach demonstrates the ability of Immuno-STAT based scaffolds to selectively engage tissue-resident T cells including intratumoral T cells of defined specificity CAMBRIDGE, Mass. , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.

- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven Almo at Albert Einstein College of Medicine - Enhances Cue Biopharma’s ability to engineer molecules for

CAMBRIDGE, Mass. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma ™, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases,

Data Highlights the Potential of the CUE-100 Series to Selectively Deliver IL-2 to Tumor-relevant T cells while Mitigating the Risk Associated with Systemic IL-2 Activation CAMBRIDGE, Mass. , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE) an innovative immunotherapy company

CAMBRIDGE, Mass. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today three poster

Research demonstrates that platform technologies generate therapeutic molecules for selective delivery of immune activating signals, such as IL-2, to disease-relevant T cells, hence avoiding systemic activation of the broader immune compartment Publication details the peptide-HLA-based platform’s

Research demonstrates Immuno-STAT™ Biologics lead to direct and selective activation and expansion of anti-viral cytotoxic T cells in vivo specific for human immunodeficiency virus (HIV) and cytomegalovirus (CMV) highlighting potential as immunotherapeutics for a variety of chronic infectious